Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 11;9(3):995-1009.
doi: 10.3390/tomography9030081.

Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging

Affiliations

Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging

Stephen M Moore et al. Tomography. .

Abstract

Preclinical imaging is a critical component in translational research with significant complexities in workflow and site differences in deployment. Importantly, the National Cancer Institute's (NCI) precision medicine initiative emphasizes the use of translational co-clinical oncology models to address the biological and molecular bases of cancer prevention and treatment. The use of oncology models, such as patient-derived tumor xenografts (PDX) and genetically engineered mouse models (GEMMs), has ushered in an era of co-clinical trials by which preclinical studies can inform clinical trials and protocols, thus bridging the translational divide in cancer research. Similarly, preclinical imaging fills a translational gap as an enabling technology for translational imaging research. Unlike clinical imaging, where equipment manufacturers strive to meet standards in practice at clinical sites, standards are neither fully developed nor implemented in preclinical imaging. This fundamentally limits the collection and reporting of metadata to qualify preclinical imaging studies, thereby hindering open science and impacting the reproducibility of co-clinical imaging research. To begin to address these issues, the NCI co-clinical imaging research program (CIRP) conducted a survey to identify metadata requirements for reproducible quantitative co-clinical imaging. The enclosed consensus-based report summarizes co-clinical imaging metadata information (CIMI) to support quantitative co-clinical imaging research with broad implications for capturing co-clinical data, enabling interoperability and data sharing, as well as potentially leading to updates to the preclinical Digital Imaging and Communications in Medicine (DICOM) standard.

Keywords: Digital Imaging and Communications in Medicine (DICOM); co-clinical imaging; metadata; open science; preclinical imaging; reproducibility; standardization.

PubMed Disclaimer

Conflict of interest statement

M.T.L. is a founder of and limited partner in StemMed Ltd., and a manager in StemMed Holdings, LP, its general partner. He is also a founder of and equity stake holder in Tvardi Therapeutics Inc.

Figures

Figure 1
Figure 1
Sample output of DICOM Analysis tool when using the Imaging Common profile.
Figure 2
Figure 2
Sample output of the DICOM Analysis tool when using the MR imaging profile. Many elements are omitted from the output for readability.

References

    1. Hormuth D.A., 2nd, Sorace A.G., Virostko J., Abramson R.G., Bhujwalla Z.M., Enriquez-Navas P., Gillies R., Hazle J.D., Mason R.P., Quarles C.C., et al. Translating preclinical MRI methods to clinical oncology. J. Magn. Reson. Imaging. 2019;50:1377–1392. doi: 10.1002/jmri.26731. - DOI - PMC - PubMed
    1. James M.L., Gambhir S.S. A molecular imaging primer: Modalities, imaging agents, and applications. Physiol. Rev. 2012;92:897–965. doi: 10.1152/physrev.00049.2010. - DOI - PubMed
    1. Van de Donk P.P., Oosting S.F., Knapen D.G., van der Wekken A.J., Brouwers A.H., Lub-de Hooge M.N., de Groot D.A., de Vries E.G. Molecular imaging to support cancer immunotherapy. J. Immunother. Cancer. 2022;10:e004949. doi: 10.1136/jitc-2022-004949. - DOI - PMC - PubMed
    1. Balasubramanian B., Venkatraman S., Myint K.Z., Janvilisri T., Wongprasert K., Kumkate S., Bates D.O., Tohtong R. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals. 2021;14:51. doi: 10.3390/ph14010051. - DOI - PMC - PubMed
    1. Clohessy J.G., Pandolfi P.P. Mouse hospital and co-clinical trial project—From bench to bedside. Nat. Rev. Clin. Oncol. 2015;12:491–498. doi: 10.1038/nrclinonc.2015.62. - DOI - PubMed

Publication types